The Global Pancreatin market share value is expected to grow at a CAGR of 5.7% from 2023-2028 to reach USD 175.7 Million by the end of 2028 from USD 104.71 million in 2022.
Pancreatin is a blend of digestive juices originating in the pancreatic organ. It includes enzymes such as it is used as a digestive aid for people with pancreatic insufficiency, a condition in which the pancreas does not produce enough digestive enzymes. It is also used as a supplement for people with digestive disorders such as cystic fibrosis, chronic pancreatitis, and pancreatitis.
Pancreatin is available in capsule, tablet, and powder form. The dosage and frequency of use depend on the individual situation and the severity of the symptoms. It is important to consult with your healthcare provider before taking this supplement to determine the appropriate dosage and avoid possible side effects. Hence, it's a mixture of digestive enzymes produced by the pancreas that help break down carbohydrates, fats, and proteins in the intestines. It is commonly used as a digestive aid for people with pancreatic insufficiency and as a supplement for indigestion. Available as capsules, tablets, and powders, it is important to consult your healthcare provider before taking the supplement to determine the proper dosage and avoid possible side effects.
The pancreatin market demand is driven by the increasing prevalence of digestive disorders such as pancreatic insufficiency, chronic pancreatitis, and cystic fibrosis. Pancreatin is used as a digestive enzyme supplement to help absorb fats, proteins, and carbohydrates in people with this condition. There is a growing geriatric population, leading to a higher prevalence of digestive disorders with age. This demographic trend is expected to increase the demand for pancreatic juice as a treatment option for the elderly with pancreatic insufficiency and other digestive disorders. Increasing awareness of the importance of maintaining digestive health is driving the demand for pancreatic enzyme supplements, including pancreatic enzymes. Consumers are becoming more proactive in managing their digestive health, which will drive the growth of the pancreatin market.
In addition, the development of advanced drug formulations, such as enteric-coated pancreatic tablets, has improved the efficacy and convenience of pancreatic products. This innovation is expected to advance the adoption of pancreatic cancer as the preferred treatment modality for pancreatic disorders. In addition, pancreatin is used in the food and beverage industry as a processing aid to produce a variety of products, including dairy, meat, and bakery products. The increasing demand for processed foods and beverages is expected to drive the growth of the pancreas market in this industry. Ongoing research and development activities in digestive health and enzyme therapy are expected to drive the pancreas market growth. This effort aims to develop more effective and targeted enzyme therapy for a variety of digestive disorders that will increase the demand for pancreatic enzymes.
The pancreatin market is influenced by the high cost of prescription drugs, which may limit their acceptance as a treatment for pancreatitis, especially in low-income countries. In addition, prescription drug marketing, disease awareness, and health and laboratory services have expanded, which may affect physician prescriptions and limit acceptance as a treatment for pancreatic cancer. In addition, the lack of long-term treatment options may also hamper the pancreas market size. Side effects of pancreatin supplements, such as nausea, vomiting, and abdominal pain, can limit tolerance, especially for people with sensitive digestive systems. The lack of use of anti-aging medications, including for the pancreas, may be related to insurance decisions, and the cost of these medications hinders the growth rate of the market.
The pancreatin market offers several opportunities for growth and expansion. The increase in digestive disorders such as primary pancreatic insufficiency and chronic pancreatitis is expected to increase the demand for pancreatic supplements as a therapeutic modality. Also, the geriatric population is increasing and leading to a higher prevalence of digestive disorders, which is expected to increase the demand for pancreatic juice as a treatment option for the elderly with pancreatic insufficiency and other digestive disorders. Furthermore, the development of advanced pharmaceutical formulations, such as enteric-coated pancreatic tablets, has increased the efficacy and convenience of pancreatic products as the preferred treatment for pancreatic disease. Along with this, the expansion of the pancreas in the food and beverage industry as a processing aid to produce a variety of products, including milk, meat, and bakery products, will drive the growth of the pancreas market in this industry. Consequently, ongoing research and development efforts in digestive health and enzyme therapy are expected to drive innovation and growth in the pancreas market. Overall, all these opportunities have fuelled the pancreatin market share.
The COVID-19 pandemic has significantly impacted the pancreatin market size in terms of both demand and supply. The global blockades and restrictions on international trade disrupted the supply chain of raw materials and finished products, affecting the availability of pancreatic supplements. Also, the pandemic has led to a shift in focus to essential healthcare products such as personal protective equipment and vaccines, which has led to a temporary decrease in demand for non-essential products such as pancreatic supplements. The COVID-19 pandemic has affected the progress of clinical trials and research in digestive health and enzyme therapy, which may affect the development of pancreatic products. Overall, the pandemic hurt the pancreatin market growth.
Based on the application, the pancreatin market is classified into pharma and nutraceuticals. The pharma segment dominates the market share since it is used in the treatment of various digestive disorders, such as pancreatic insufficiency, chronic pancreatitis, and cystic fibrosis, and to help absorb fats, proteins, and carbohydrates. As lifestyle and eating habits are changing, the prevalence of these diseases increases, which therefore contributes to the market share of the pharma segment. The nutraceuticals segment has a growing market share due to its use in the food industry as a dietary supplement to increase weight, increase strength and physical activity, and improve quality of life. In addition, digestive enzymes are used as processing aids in the food industry to produce a variety of products, including dairy, meat, and bakery products.
Based on the source, the pancreatin market is divided into Porcine and Bovine; the porcine segment dominates the market share since porcine pancreatin is more similar to human pancreatin in terms of its enzyme composition and activity. Also it is also more stable and has a longer shelf life than bovine pancreatin. Moreover, the availability of porcine pancreatin is more than that of bovine. The bovine segment has significant market growth, as it is only used in specialized disorders.
Based on the form, the pancreatin market is classified into powder and pellets. The powder segment dominates the market share since the powdered form increases the availability and can be measured easily. It is also easier to produce and formulate, more versatile, and can be used in a wider range of applications.
North America dominates the market share with the rising digestive disorders and chronic gastrointestinal issues due to lifestyle and eating disorders, which caused a huge demand for pancreatin products. Europe has the largest market share due to the increase in geriatric population and the rise in chronic population, and it has driven the demand for pancreatin nutraceuticals. Asia Pacific has significant market growth because of the increase in digestive disorders and the increase in cases of digestive ulcers. Latin America has steady market growth as disposable income is increasing, which has led to a rise in gastrointestinal issues among people, leading to pancreatin therapy. At the same time, the Middle East and Africa have low market share compared to other regions.
Key Players in the Market:
Major Key Players in the Global Pancreatin Market are
Frequently Asked Questions
The increasing prevalence of gastrointestinal chronic illnesses is the major driving factor.
The market is estimated to register a CAGR of 5.7% during the forecast period.
The major players AbbVie Inc., Novo Nordisk A/S, Nordmark Arzneimittel GmbH & Co. KG, Shenzhen Hepalink Pharmaceuticals Co., Ltd, Sichuan Deebio Pharmaceutical Co., Ltd, and Biovencer Healthcare Private Limited.
High Cost of the pancreatin drug is one of the challenging factors for the pancreatin market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region